Abstract | BACKGROUND: METHODS: This study included patients treated with the anti-PD-1 antibodies nivolumab or pembrolizumab at Fujita Health University Hospital between December 2015 and March 2019. We retrospectively reviewed the electronic medical records for age, cancer type, pre-treatment blood test data, presence or absence of irAE onset, type and severity of irAEs, outcome of irAE treatment, response rate, progression-free survival and overall survival. RESULTS: Two hundred-eighty patients received ICIs. The overall incidence of irAEs was 41.1% (115 patients), and the incidence of severe irAEs of grade 3 and higher was 2.8% (eight patients). The most common irAEs were skin disorders, thyroid disorders and interstitial pneumonitis. Patients with irAEs were significantly older than those without irAEs (69.7 versus 66.0 years, P = 0.02). The objective response rate (ORR) in patients with irAEs was 30.4%, which was significantly higher than in patients without irAEs (12.7%; P < 0.01). Both the median overall and progression-free survival were significantly longer in patients with irAEs (P < 0.01, p < 0.01). Based on the blood test data obtained before ICI therapy, hypothyroidism, thyroid-stimulating hormone levels and thyroglobulin antibody levels were associated with the onset of irAEs. In many patients with irAEs of Common Terminology Criteria for Adverse Events Grade 3 or higher, re-administration of ICIs was difficult, and their outcomes were poor. In contrast, many patients with irAEs of a lower grade were able to resume ICI therapy. CONCLUSION: Although the onset of irAEs was difficult to be predicted based on pre-treatment tests. It appeared that the continuation of ICI therapy, along with early detection and adequate control of irAEs, might contribute to the improved prognosis of patients.
|
Authors | Hiroshi Matsuoka, Takahiro Hayashi, Karen Takigami, Kazuyoshi Imaizumi, Ryoichi Shiroki, Naoki Ohmiya, Kazumitsu Sugiura, Kenji Kawada, Akira Sawaki, Koutaro Maeda, Yousuke Ando, Ichiro Uyama |
Journal | BMC cancer
(BMC Cancer)
Vol. 20
Issue 1
Pg. 656
(Jul 14 2020)
ISSN: 1471-2407 [Electronic] England |
PMID | 32664888
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
- Nivolumab
- pembrolizumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Drug-Related Side Effects and Adverse Reactions
(epidemiology, etiology, pathology)
- Female
- Follow-Up Studies
- Humans
- Incidence
- Japan
(epidemiology)
- Male
- Middle Aged
- Neoplasms
(drug therapy, immunology, pathology)
- Nivolumab
(administration & dosage)
- Prognosis
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors)
- Retrospective Studies
- Survival Rate
- Young Adult
|